A world-class atherosclerosis R&D company.
Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The lead product candidate, the fully human antibody PC-mAb, is in clinical development. In addition, Athera has developed a biomarker and companion diagnostic CVDefine® kit. The biomarker, anti-PC, is linked to increased risk for cardiovascular disease and could in the future be used for identification of patients that benefit from Athera’s novel therapeutics.
PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine (“PC”). Naturally occurring antibodies to phosphorylcholine (anti-PC) have anti-inflammatory properties. Low endogenous levels of antibodies to phosphorylcholine (“anti-PC”) have been linked to a higher incidence of secondary events in CVD.
Athera’s PC-mAb is targeting the market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. This program is in clinical Phase I studies. According to plan, the data will enable a business agreement with Athera and a partner. PC-mAb could then be launched on the market as a new drug, with clear block-buster potential, by year 2020.
To enhance clinical success by properly selecting the target population, Athera has developed a proprietary companion diagnostic CVDefine® kit to identify patients with low anti-PC levels in need of receiving PC-mAb therapy. The kit is CE-approved.
Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). The Company initiated its current program in 2005, harnessing breakthrough innovations made at the world-renowned Karolinska Institutet, Solna, Sweden. The company currently has a proprietary clinical development stage program, PC-mAb, supported by an approved proprietary companion diagnostic kit. Future development costs for the antibody therapy will be co-financed by the EU FP7 program, in the project CARDIMMUN. Athera is managed by a core team of senior professionals from the pharmaceutical and diagnostics industries in a semi-virtual organization.
Carina Schmidt, CEO
Knut Pettersson, VP Preclinical development
Tommy Abrahamsson, Senior Advisor CVD pharmaceuticals
Anders Bergman, VP IP/Legal
board of directors.
Gunnar Olsson, MD, PhD
Chairman, former head of CV/GI in AstraZeneca
Otto Skolling, MSc
Jonas Brambeck, MSc
Svein Mathisen, MSc
Former CEO of Bioinvent International (publ)
Kallelse till årsstämma i Athera Biotechnologies AB (Swedish only)
Mar 31, 2017.
Kontantemission i Athera Biotechnologies AB (Swedish only)
Mar 27, 2017.
Athera initiates multiple dosing trial with its fully human antibody PC-mAb
Jan 30, 2017.
Low levels of endogenous anti-PC identified as a novel risk factor for vein bypass graft failure and cardiovascular complications in PAD patients
Sep 29, 2016.
Athera presents positive First-in-Patient data with their new antibody against immunovascular disease at ESVS
Sep 28, 2016.
Athera is the leading SME partner in the FP7 EU-project CARDIMMUN. The project involves 5 partners, also including Smerud Medical Research International AS, Clinical Trial Consultants AB, Turku Pet Center and Leiden University Medical Center. LUMC is the project coordinator and will be leading the project together with Athera.
CARDIMMUN aims to pursue development of the scientific findings from the FP6 project CVDImmune. Based on patented discoveries in Athera Biotechnologies AB, that low levels of anti-PC (phosphorylcholine) indicate risk for future development of cardiovascular disease, we have developed both a diagnostic test (a marker to identify cardiovascular disease patients that are at high risk of secondary events) and a candidate drug – an innovative fully human monoclonal antibody antibody, PC-mAb – that can block vascular inflammation. Together, this forms a unique opportunity for a personalised medicine approach, with a companion diagnostic and a targeted intervention in an area that is still in great medical need, despite recent advances in therapy. PC-mAb is now ready for clinical development.
The project will be progressed, by a structured plan that brings together SMEs and selected academic partners, and integrates preclinical and clinical studies into a commercially viable and mature therapeutic modality. The 5 work packages will embrace concept testing in preclinical models using biomarkers applicable also in human disease, coronary flow reserve and glucose uptake in inflamed arteries, as well as required toxicity studies. Additionally, studies in man are planned that explores safety, pharmacokinetics, pharmacodynamics and indices of clinical efficacy, including a placebo-controlled Proof of Activity trial in patients.
CARDIMMUN receives funding from the European Union, Seventh Framework Programme.
Carina Schmidt, CEO
Reg. No. 556620-6859
Telephone: +46 76 1938 190
Athera Biotechnologies AB
Sankt Eriksgatan 117, 4th floor
113 43 Stockholm, Sweden
Athera is located at Business Center Bilpalatset, next to Hagastaden and the new Karolinska Hospital.